Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04331899 · ClinicalTrials.gov registry record · Phase 2
Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT04331899: Completed Phase 2 study, sponsored by Stanford University.
NCT04331899 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04331899, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
To evaluate the efficacy of a single dose of subcutaneous injections of 180 ug of Peginterferon Lambda-1a, compared with placebo in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.
Interventions
- OTHER Placebo
- DRUG Peginterferon Lambda-1a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-04-25 |
| Est. Completion | 2021-05-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04331899
The ClinicalTrials.gov registry entry for NCT04331899 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04331899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04331899 about?
NCT04331899 is a clinical study titled "Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19". To evaluate the efficacy of a single dose of subcutaneous injections of 180 ug of Peginterferon Lambda-1a, compared with placebo in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.
What is the current status of trial NCT04331899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2020-04-25. Estimated completion is 2021-05-06.
What interventions are being tested in trial NCT04331899?
The interventions under investigation include: Placebo (OTHER), Peginterferon Lambda-1a (DRUG).
Who is sponsoring clinical trial NCT04331899?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.